

## UNITED STATES PATENT AND TRADEMARK OFFICE

M

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/539,107	06/15/2005	Tomasz Heyduk	102364	2295
277.0	7590 03/16/200 SHALTON FLANIGA	EXAMINER		
700 W. 47TH S	TREET	SCHNIZER, RICHARD A		
SUITE 1000 KANSAS CITY	Y, MO 64112-1802		ART UNIT	PAPER NUMBER
	•	1635		
SHORTENED STATUTOR	Y PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
31 DAYS		03/16/2007	PAPER	

## Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

	Application No.	Applicant(s)			
	10/539,107	HEYDUK ET AL.			
Office Action Summary	Examiner	Art Unit			
	Richard Schnizer, Ph. D.	1635			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING ID.  - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statuted Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNIC 136(a). In no event, however, may a red will apply and will expire SIX (6) MON te, cause the application to become AB	CATION. eply be timely filed THS from the mailing date of this communication. EANDONED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on  2a) This action is <b>FINAL</b> . 2b) Thi  3) Since this application is in condition for allowed closed in accordance with the practice under	is action is non-final. ance except for formal matte				
Disposition of Claims					
4) ⊠ Claim(s) <u>109-130</u> is/are pending in the application 4a) Of the above claim(s) is/are withdrays 5) □ Claim(s) is/are allowed.  6) □ Claim(s) is/are rejected.  7) □ Claim(s) is/are objected to.  8) ⊠ Claim(s) <u>109-130</u> are subject to restriction and	awn from consideration.				
Application Papers		•			
9) The specification is objected to by the Examin	er.				
10) The drawing(s) filed on is/are: a) ac	cepted or b)  objected to l	by the Examiner.			
Applicant may not request that any objection to the	e drawing(s) be held in abeyan	ce. See 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the E	•	, , , ,			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreig a) All b) Some * c) None of:  1. Certified copies of the priority documen 2. Certified copies of the priority documen 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	nts have been received. Its have been received in Apority documents have been au (PCT Rule 17.2(a)).	pplication No received in this National Stage			
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	Paper No(s	summary (PTO-413) s)/Mail Date nformal Patent Application			

## **DETAILED ACTION**

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

Molecular biosensors comprising 2 or more epitope binding agents selected from the group consisting of aptamers, antibodies, and double stranded nucleic acids.

Applicant is required, in reply to this action, to elect a single biosensor having 2 or more epitope binding agents, and to identify each epitope binding agent in the biosensor as an epitope, an antibody, or a double stranded nucleic acid. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The claims are deemed to correspond to the species listed above in the following manner, wherein dsNA = double stranded nucleic acid:

Species Claim

Application/Control Number: 10/539,107

Art Unit: 1635

antibody/antibody	109-111, 116, 118-127
antibody/aptamer	109-111, 114, 118-127
antibody/dsNA	109-111, 115, 118-127
aptamer/aptamer	109-112, 118-129
aptamer/dsNA	109-111, 113, 118-127
dsNA/dsNA	109-111, 117-127
antibody/antibody/antibody	130
antibody/antibody/aptamer	130
antibody/antibody/dsNA	130
antibody/aptamer/dsNA	130
aptamer/aptamer/aptamer	130
aptamer/aptamer/antibody	130
aptamer/aptamer/dsNA	130
dsNA/dsNA/dsNA	130
dsNA/dsNA/antibody	130
dsNA/dsNA/aptamer	130

The following claim(s) are generic: claims 109-111, 118-127, and 130.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: The epitope binding agents are from different art-recognized classes of molecules. The antibodies lack any structural feature in common with the nucleic acids and the aptamers because the antibodies are polypeptides and the aptamers and nucleic acids are not. The nucleic acids and aptamers are judged to lack any significant common structural feature because although they are both nucleic acids, aptamers are generally single stranded nucleic acids that fold up to assume a particular secondary and tertiary structure that recognizes an epitope, whereas double stranded nucleic acids, in view of the specification as a whole are intended to refer to e.g. sites for DNA-binding proteins, and comprise separate single stranded molecules joined by hybridization of complementary base pairs.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

Art Unit: 1635

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner(s) should be directed to Richard Schnizer, whose telephone number is 571-272-0762. The examiner can normally be reached Monday through Friday between the hours of 6:00 AM and 3:30. The examiner is off on alternate Fridays, but is sometimes in the office anyway.

If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, J. Douglas Schultz, can be reached at (571) 272-0763. The official central fax number is 571-273-8300. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system

Art Unit: 1635

provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Richard Schnizer, Ph.D.

**Primary Examiner** 

Art Unit 1635